(RS)-8-chloro-1-[4-(4-fluoro-phenyl)cyclohex-3-enyl]-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene | 1339125-67-5

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: (RS)-8-chloro-1-[4-(4-fluoro-phenyl)cyclohex-3-enyl]-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene
• 英文别名: 8-Chloro-1-[4-(4-fluorophenyl)cyclohex-3-en-1-yl]-5-methyl-4,6-dihydro-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
• CAS: 1339125-67-5
• 化学式: C₂₃H₂₂ClFN₄
• 分子量: 408.906
• InChiKey: SWUSHKFEFZBDOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  29
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  34
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• ARYL-/HETEROARYL-CYCLOHEXENYL-TETRAAZABENZO[E]AZULENES
  申请人：Dolente Cosimo

  公开号：US20110251183A1

  公开（公告）日：2011-10-13

  The present invention is concerned with aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes of formula I wherein R 1 , R 2 and R 3 are as described herein. The invention further provides methods for the manufacture of such compounds and pharmaceutical compositions containing them. The compounds according to the invention act as V1 a receptor modulators, and in particular as V1 a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

  本发明涉及式I的芳基/杂芳基环己烯基四氮杂苯并[e]吲哚啉类化合物 其中R1，R2和R3如本文所述。本发明还提供了制造此类化合物的方法和含有它们的药物组合物。根据发明的化合物作为V1a受体调节剂，特别是作为V1a受体拮抗剂，它们的制造，含有它们的药物组合物以及它们作为药物的使用。本发明的活性化合物作为治疗剂在末梢和中央条件下痛经，男性或女性性功能障碍，高血压，慢性心力衰竭，不适当的抗利尿激素分泌，肝硬化，肾病综合征，焦虑，抑郁障碍，强迫症，自闭症谱系障碍，精神分裂症和侵略性行为中是有用的。
• [EN] ARYL - /HETEROARYL - CYCLOHEXENYL - TETRAAZABENZO [E] AZULENES AS VASOPRESSIN ANTAGONISTS<br/>[FR] ARYL-/HÉTÉROARYL-CYCLOHEXÉNYL-TÉTRAAZABENZO[E]AZULÈNES EN TANT QU'ANTAGONISTES DE VASOPRESSINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011128265A1

  公开（公告）日：2011-10-20

  The present invention is concerned with aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes of formula I wherein R1, R2 and R3 are as described herein. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

  本发明涉及式I的芳基/杂芳基环己烯基四氮杂苯并[e]吲哚啉，其中R1、R2和R3如本文所述。根据发明的化合物作为V1a受体调节剂，尤其是作为V1a受体拮抗剂，它们的制造、含有它们的药物组合物以及它们作为药物的使用。本发明的活性化合物作为治疗剂，在痛经、男性或女性性功能障碍、高血压、慢性心力衰竭、不适当分泌的抗利尿激素、肝硬化、肾病综合征、焦虑症、抑郁症、强迫症、自闭症谱系障碍、精神分裂症和侵略性行为的条件下，在周围和中心发挥作用。
• ARYL - /HETEROARYL - CYCLOHEXENYL - TETRAAZABENZO [E]AZULENES AS VASOPRESSIN ANTAGONISTS
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2558467A1

  公开（公告）日：2013-02-20
• ARYL-/HETEROARYL-CYCLOHEXENYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN ANTAGONISTS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2558467B1

  公开（公告）日：2017-05-17
• US8461151B2
  申请人：——

  公开号：US8461151B2

  公开（公告）日：2013-06-11